Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (291)	8/26/2002 8:06:20 PM
From: mopgcw	Respond to of 598

Quite exciting. Finally. I am so tired of averaging down this one... regards, george

To: tuck who wrote (291)	8/26/2002 8:35:33 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 598

>>Banc of America downgrades to MKT PERFORM from Buy; believes Aug 26 FDA meeting on the development plan for T-67 adds risk without commensurate reward; sees odds of an FDA endorsement of the T-67 Phase III trial at just 60-40<< I wondered at the time how B of A handicapped the odds. I guess they assumed an FDA OK was unlikely since they were changing the dosage regimen. The go-ahead suggests TLRK was able to present a pretty strong case for T67's safety: In May, Tularik disclosed data from Phase 2 human clinical trials using T67 at a dose of 165mg/m(2) administered intravenously every week to patients with HCC. The low incidence of adverse events and hematologic toxicity in that Phase 2 study, together with a related pharmacokinetic analysis, supports conducting the planned pivotal trial using a dose of 250mg/m(2) given by intravenous infusion every week. Perhaps as fair disclosure B of A might have added: "Making an investment decision based on our downgrade adds risk without commensurate reward." I, too, welcome the good news. Now I'm looking forward to an upcoming announcement on initiation of Phase I trials for their still unnamed soon-to-be-a-major-motion-picture compound.